Atlas Legacy Advisors LLC Purchases 229 Shares of AbbVie Inc. $ABBV

Atlas Legacy Advisors LLC increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 21.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,282 shares of the company’s stock after acquiring an additional 229 shares during the period. Atlas Legacy Advisors LLC’s holdings in AbbVie were worth $238,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Savant Capital LLC boosted its stake in AbbVie by 9.8% in the second quarter. Savant Capital LLC now owns 171,715 shares of the company’s stock worth $31,874,000 after purchasing an additional 15,296 shares in the last quarter. Texas Yale Capital Corp. lifted its position in AbbVie by 10.2% during the 2nd quarter. Texas Yale Capital Corp. now owns 41,898 shares of the company’s stock worth $7,777,000 after buying an additional 3,890 shares in the last quarter. OneAscent Wealth Management LLC lifted its position in AbbVie by 33.6% during the 2nd quarter. OneAscent Wealth Management LLC now owns 2,434 shares of the company’s stock worth $452,000 after buying an additional 612 shares in the last quarter. Modera Wealth Management LLC grew its holdings in AbbVie by 1.5% during the 2nd quarter. Modera Wealth Management LLC now owns 76,027 shares of the company’s stock worth $14,112,000 after acquiring an additional 1,088 shares during the last quarter. Finally, Twin Capital Management Inc. increased its position in AbbVie by 3.5% in the 2nd quarter. Twin Capital Management Inc. now owns 40,405 shares of the company’s stock valued at $7,500,000 after acquiring an additional 1,359 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of ABBV opened at $218.92 on Friday. The stock has a market cap of $386.74 billion, a P/E ratio of 104.25, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81. The stock’s 50-day moving average price is $223.24 and its two-hundred day moving average price is $202.30. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the company posted $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ABBV. Morgan Stanley upped their target price on shares of AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. HSBC set a $225.00 price objective on AbbVie in a report on Thursday, October 2nd. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Evercore ISI boosted their target price on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Finally, Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $236.57.

Insider Activity

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.25% of the stock is owned by company insiders.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.